Latest News

Investors are bullish on Palantir's stock due to not only the company's strong growth but also a convincing vision from CEO Alex Karp.

Reaching the very top of the credit scale takes decades of near-flawless habits, and most people get the same perks without ever getting there.

PayPal's stock has cratered, but a new CEO, strong cash flow, and AI commerce bets could change the story. Here's what to watch.

Although Bitcoin probably isn't going away, within five years it will be vulnerable to significant disruption.

Realty Income offers a high yield, and it's been raising its payout for decades.

Sometimes an investor's thesis for buying is better than the reasons for selling.

This exchange-traded fund has more than 70% of its assets parked in technology stocks.

Oportun Financial (NASDAQ:OPRT) said it has built a more resilient earnings platform through sustained profitability, improving credit performance, lower funding costs and stronger liquidity, while shifting its focus toward durable risk-adjusted growth. Speaking at the Sidoti September Small-Cap Vi

Read inspirational quotes about finding your passion, building a powerful routine and conquering fear.

SpaceX is a major Nvidia client.

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

AI is disrupting the tech world, but these companies are quickly adapting.

Nvidia is today’s AI chip leader.

“A sound investment can morph into a rash of speculation if it is bought at an elevated price,” according to the Oracle of Omaha.

I have a plan to avoid long-term financial stress.

This isn't your typical S&P 500 ETF.

Tullow Oil (LON:TLW) said strong production performance, high realized oil prices and progress on Ghana receivables led it to raise its 2026 free cash flow guidance, while the company also outlined expanded drilling and exploration opportunities around its Jubilee and TEN fields. Chief Executive Of

Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate

Can ads and price hikes produce the 11% a year it'd take?